HALOZYME THERAPEUTICS, INC. Amortization of Intangible Assets
HALOZYME THERAPEUTICS, INC. (HALO) reported Amortization of Intangible Assets of $29.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $29.51M, a 66.15% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $29.51M, a 66.15% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $23.38M, a 31.61% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $17.76M, a 0.00% change year-over-year.
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2025 was $76.66M, a 7.90% increase from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2024 was $71.05M, a 3.69% decline from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2023 was $73.77M, a 70.98% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2022 was $43.15M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.51M 10-Q · filed 2026-08-06 | $59.02M 10-Q · filed 2026-08-06 | $82.40M derived: sum of 3 quarters · filed 2026-08-06 | $100.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $29.51M 10-Q · filed 2026-05-11 | $52.89M derived: sum of 2 quarters · filed 2026-05-11 | $70.65M derived: sum of 3 quarters · filed 2026-05-11 | $88.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $41.14M derived: sum of 2 quarters · filed 2026-02-17 | $58.90M derived: sum of 3 quarters · filed 2026-08-06 | $76.66M 10-K · filed 2026-02-17 |
| 2025-09-30 | $17.76M 10-Q · filed 2025-11-03 | $35.52M derived: sum of 2 quarters · filed 2026-08-06 | $53.29M 10-Q · filed 2025-11-03 | $71.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.76M 10-Q · filed 2026-08-06 | $35.52M 10-Q · filed 2026-08-06 | $53.29M derived: sum of 3 quarters · filed 2026-08-06 | $71.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $17.76M 10-Q · filed 2026-05-11 | $35.52M derived: sum of 2 quarters · filed 2026-05-11 | $53.29M derived: sum of 3 quarters · filed 2026-05-11 | $71.05M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $17.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $35.52M derived: sum of 2 quarters · filed 2026-02-17 | $53.29M derived: sum of 3 quarters · filed 2026-02-17 | $71.05M 10-K · filed 2026-02-17 |
| 2024-09-30 | $17.76M 10-Q · filed 2025-11-03 | $35.52M derived: sum of 2 quarters · filed 2025-11-03 | $53.29M 10-Q · filed 2025-11-03 | $71.05M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $17.76M 10-Q · filed 2025-08-05 | $35.52M 10-Q · filed 2025-08-05 | $53.29M derived: sum of 3 quarters · filed 2026-02-17 | $73.63M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $17.76M 10-Q · filed 2025-05-06 | $35.52M derived: sum of 2 quarters · filed 2026-02-17 | $55.87M derived: sum of 3 quarters · filed 2026-02-17 | $73.70M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $17.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $38.10M derived: sum of 2 quarters · filed 2026-02-17 | $55.94M derived: sum of 3 quarters · filed 2026-02-17 | $73.77M 10-K · filed 2026-02-17 |
| 2023-09-30 | $20.34M 10-Q · filed 2024-10-31 | $38.18M derived: sum of 2 quarters · filed 2024-10-31 | $56.01M 10-Q · filed 2024-10-31 | $60.56M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $17.84M 10-Q · filed 2024-08-06 | $35.67M 10-Q · filed 2024-08-06 | $40.22M derived: sum of 3 quarters · filed 2025-02-18 | $67.42M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $17.84M 10-Q · filed 2024-05-07 | $22.39M derived: sum of 2 quarters · filed 2025-02-18 | $49.58M derived: sum of 3 quarters · filed 2025-02-18 | $60.98M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $31.75M derived: sum of 2 quarters · filed 2025-02-18 | $43.15M derived: sum of 3 quarters · filed 2025-02-18 | $43.15M 10-K · filed 2025-02-18 |
| 2022-09-30 | $27.19M 10-Q · filed 2023-11-06 | $38.60M derived: sum of 2 quarters · filed 2023-11-06 | $38.60M 10-Q · filed 2023-11-06 | $38.60M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $11.40M 10-Q · filed 2023-08-08 | $11.40M 10-Q · filed 2023-08-08 | $11.40M derived: sum of 3 quarters · filed 2024-02-20 | $11.40M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 derived: sum of 3 quarters · filed 2024-02-20 | $0.00 derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 derived: sum of 3 quarters · filed 2024-02-20 | $0.00 10-K · filed 2024-02-20 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |